A Clear Watering Down: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Vote The Clear Labels Act, a landmark bill aimed at increasing transparency in the generic drug industry, has been stripped of two critical provisions ahead of its full Senate vote.
Senators Rick Scott and Kirsten Gillibrand's legislation was designed to allow doctors and patients to see where their medications were made.
The original bill was a response to the ProPublica investigation last year that revealed thousands of reported adverse reactions in patients linked to generic drugs made at foreign factories with quality and safety lapses.